Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Planas

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2007
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rateM Diago, A Olveira, R Solá, et al.
Respiratory Research|April 23, 2026
A prospective cohort study for characterization and predictive factors of long-term POST-COVID interstitial changesM Hernandez-Argudo, J Bordas-Martinez, V Vicens-Zygmunt, et al.
Breast Disease|September 20, 2021
Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsyS Salinas-Huertas, A Luzardo-González, S Vázquez-Gallego, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2007
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rateM Diago, A Olveira, R Solá, et al.
Respiratory Research|April 23, 2026
A prospective cohort study for characterization and predictive factors of long-term POST-COVID interstitial changesM Hernandez-Argudo, J Bordas-Martinez, V Vicens-Zygmunt, et al.
Breast Disease|September 20, 2021
Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsyS Salinas-Huertas, A Luzardo-González, S Vázquez-Gallego, et al.
Pageof 13